Clovis Oncology announced its preliminary, unaudited revenues for the fourth quarter and full year ended December 31, 2018. The financial information may be adjusted as a result of completion of customary quarterly review and audit procedures. Unaudited preliminary results include: $30.3M-$30.8M in Rubraca product revenues for 4Q18 compared to $22.8M for Q318 and $17M for Q417. $95.3M-$95.8M in Rubraca product revenues for FY18 compared to $55.5M for FY17. Free drug was an additional approximately 25% to 27% of overall commercial supply for Q4 and FY18. $518M-$521M in cash, cash equivalents and available-for-sale securities at December 31, 2018. Clovis plans to discuss these results with investors this week at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.